Drug resistance-related miRNAs in hepatocellular cancer

References

• Hong L, Han Y, Li S, et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 2010;10(12):1693-701
   PubMed Web of Science ®Google Scholar
• Melo SA, Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res 2012;18(16):4234-9
   PubMed Web of Science ®Google Scholar
• Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010;17(8):523-31
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis 2012;33(6):1126-33
   PubMed Web of Science ®Google Scholar
• miRBase. Available from: www.miRbase.org/index.shtml
   Google Scholar
• Chen PS, Su JL, Hung MC. Dysregulation of microRNAs in cancer. J Biomed Sci 2012;19:90
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, et al. miR-210: a therapeutic target in cancer. Expert Opin Ther Targets 2013;17(1):21-8
   PubMed Web of Science ®Google Scholar
• Nana-Sinkam SP, Croce CM. MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs. IDrugs 2010;13(12):843-6
   PubMed Web of Science ®Google Scholar
• Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther 2011;18(12):1121-6
   PubMed Web of Science ®Google Scholar
• Kim JK, Noh JH, Jung KH, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 2013;57(3):1055-67
   PubMed Web of Science ®Google Scholar
• Gandellini P, Profumo V, Folini M, Zaffaroni N. MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets 2011;15(3):265-79
   PubMed Web of Science ®Google Scholar
• Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics 2012;4(4):369-81
   PubMed Web of Science ®Google Scholar
• Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010;46(2):298-311
   PubMed Web of Science ®Google Scholar
• Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer 2010;126(1):2-10
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang H, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010;251(6):1056-63
   PubMed Web of Science ®Google Scholar
• Neelakandan K, Babu P, Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr Cancer Drug Targets 2012;12(6):716-40
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang Y, Zhen P, et al. Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines. PLoS One 2013;8(1):e54111
   PubMed Web of Science ®Google Scholar
• Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1(3-4):144-58
   PubMed Web of Science ®Google Scholar
• Porcelli L, Quatrale AE, Mantuano P, et al. Synthetic lethality to overcome cancer drug resistance. Curr Med Chem 2012;19(23):3858-73
   PubMed Web of Science ®Google Scholar
• Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012;1(2):62-70
   PubMed Web of Science ®Google Scholar
• Ang C, O’Reilly EM, Abou-Alfa GK. Targeted agents and systemic therapy in hepatocellular carcinoma. Recent Results Cancer Res 2013;190:225-46
   PubMedGoogle Scholar
• Hida K, Akiyama K, Ohga N, et al. Tumour endothelial cells acquire drug resistance in a tumour microenvironment. J Biochem 2013;153(3):243-9
   PubMed Web of Science ®Google Scholar
• Avner BS, Fialho AM, Chakrabarty AM. Overcoming drug resistance in multi-drug resistant cancers and microorganisms: a conceptual framework. Bioengineered 2012;3(5):262-70
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Chekhonin VP. Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential. Eur J Pharmacol 2012;684(1-3):8-18
   PubMed Web of Science ®Google Scholar
• Salehan MR, Morse HR. DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci 2013;70(1):31-40
   PubMed Web of Science ®Google Scholar
• Jorfi S, Inal JM. The role of microvesicles in cancer progression and drug resistance. Biochem Soc Trans 2013;41(1):293-8
   PubMed Web of Science ®Google Scholar
• Wu X, Xiao H. miRNAs modulate the drug response of tumor cells. Sci China C Life Sci 2009;52(9):797-801
   PubMedGoogle Scholar
• Hong L, Han Y, Zhou Y, Nita A. Angiogenesis-related microRNAs in colon cancer. Expert Opin Biol Ther 2013;13(1):77-84
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Mishra PJ, Banerjee D, Bertino JR. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle 2008;7(7):853-8
   PubMed Web of Science ®Google Scholar
• Hong L, Yang Z, Ma J, Fan D. Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets 2013;14(10):1118-27
   PubMed Web of Science ®Google Scholar
• Tian W, Chen J, He H, Deng Y. MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin Transl Oncol 2013;15(5):335-42
   PubMed Web of Science ®Google Scholar
• Wang Z, Li Y, Ahmad A, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 2010;13(4-5):109-18
   PubMed Web of Science ®Google Scholar
• Sarkar FH, Li Y, Wang Z, et al. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010;13(3):57-66
   PubMed Web of Science ®Google Scholar
• Meng F, Glaser SS, Francis H, et al. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med 2012;16(1):160-73
   PubMed Web of Science ®Google Scholar
• Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008;13(10):1215-22
   PubMed Web of Science ®Google Scholar
• Nagano H, Kobayashi S, Marubashi S, et al. Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus. Exp Ther Med 2013;5(1):3-10
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010;103(10):1617-26
   PubMed Web of Science ®Google Scholar
• Hong L, Han Y, Zhang Y, et al. MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets 2013;17(9):1073-80
   PubMed Web of Science ®Google Scholar
• Tomokuni A, Eguchi H, Tomimaru Y, et al. miR-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2011;414(4):675-80
   PubMed Web of Science ®Google Scholar
• Xu N, Shen C, Luo Y, et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun 2012;425(2):468-72
   PubMed Web of Science ®Google Scholar
• Ma K, He Y, Zhang H, et al. DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 2012;287(8):5639-49
   PubMed Web of Science ®Google Scholar
• Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013;58(2):629-41
   PubMed Web of Science ®Google Scholar
• Fornari F, Milazzo M, Chieco P, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010;70(12):5184-93
   PubMed Web of Science ®Google Scholar
• Xu Y, Xia F, Ma L, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011;310(2):160-9
   PubMed Web of Science ®Google Scholar
• Xu N, Zhang J, Shen C, et al. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 2012;423(4):826-31
   PubMed Web of Science ®Google Scholar
• Yang F, Li QJ, Gong ZB, et al. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Hong L, Han Y, Lu Q, et al. Drug resistance-related microRNAs in esophageal cancer. Expert Opin Biol Ther 2012;12(11):1487-94
   PubMed Web of Science ®Google Scholar
• Chen Z, Ma T, Huang C, et al. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Cell Signal 2013;25(12):2693-701
   PubMed Web of Science ®Google Scholar
• Yang T, Zheng ZM, Li XN, et al. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. Exp Biol Med (Maywood) 2013;238(9):1024-32
   PubMed Web of Science ®Google Scholar
• Borel F, Han R, Visser A, et al. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 2012;55(3):821-32
   PubMed Web of Science ®Google Scholar